Search

Displaying results 1961 - 1970 of 6951 in total
  1. Drug

    Bisoprolol

    go.drugbank.com/drugs/DB00612
    ApprovedInvestigational

    [A180472,L7219] It is considered a potent drug with a long-half life that can be used once daily to reduce the need for multiple doses of antihypertensive drugs. … [A180472] Bisoprolol is generally well tolerated, likely due to its β1-adrenergic receptor selectivity and is a useful alternative to non-selective β-blocker drugs in the treatment of hypertension such

    Categories: Antihypertensive Agents Indicated for Hypertension, Adrenergic beta-1 Receptor Antagonists
  2. Drug

    Bismuth subnitrate

    go.drugbank.com/drugs/DB13209
    ApprovedWithdrawn

    Bismuth subnitrate, also referred to as bismuth oxynitrate or bismuthyl nitrate, is a highly water-soluble crystalline compound that has been used as a treatment for duodenal ulcers and anti-diarrheic

    Categories: Drugs for Acid Related Disorders, Drugs for Peptic Ulcer and Gastro-Oesophageal Reflux Disease (Gord)
  3. Drug

    Boceprevir

    go.drugbank.com/drugs/DB08873
    ApprovedWithdrawn

    with [DB00811], [DB00008], and [DB00022] as first line therapy for Hepatitis C [A19593]. … Boceprevir is available as a fixed dose product (tradename Victrelis) used for the treatment of chronic Hepatitis C.

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  4. Drug

    Flibanserin

    go.drugbank.com/drugs/DB04908
    ApprovedInvestigational

    Flibanserin is the first drug to be approved for hypoactive sexual desire disorder (HSDD) in premenopausal women by the FDA in August 2015. … In February of 2018 Flibanserin was approved by Health Canada under the brand name Addyi for a similar indication as approved by the FDA.

    Categories: Serotonin Receptor Agonists, Serotonin Receptor Antagonists
  5. Drug

    Naltrexone

    go.drugbank.com/drugs/DB00704
    ApprovedInvestigationalVet approved

    The FDA has approved naltrexone for the treatment of alcohol dependence. … It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction.

  6. Drug

    Glutathione

    go.drugbank.com/drugs/DB00143
    ApprovedInvestigationalNutraceutical

    It conjugates to drugs to make them more soluble for excretion, is a cofactor for some enzymes, is involved in protein disulfide bond rearrangement and reduces peroxides.

  7. Drug

    Sparsentan

    go.drugbank.com/drugs/DB12548
    ApprovedInvestigational

    Sparsentan is a dual antagonist of the endothelin type A receptor (ET<sub>A</sub>R) and the angiotensin II (Ang II) type 1 receptor (AT<sub>1</sub>R) with a similar affinity for both (9.3 nM for ET<sub … >A</sub>R and 0.8 nM for AT<sub>1</sub>R).

    Categories: Angiotensin 2 Receptor Blocker, Dual Endothelin Type A Receptor/Ang II Subtype 1 Receptor Antagonist (DEARA)
  8. Drug

    Tianeptine

    go.drugbank.com/drugs/DB09289
    Investigational

    Tianeptine is a drug used primarily in the treatment of major depressive disorder and has been studied in the treatment of irritable bowel syndrome (IBS) . Structurally, it is classified as a tricyclic antidepressant (TCA), however, it p...

  9. Drug

    Glofitamab

    go.drugbank.com/drugs/DB16371
    ApprovedInvestigational

    /CD3 bispecific monoclonal antibody approved for DLBCL. … [L45768,A258433] In the context of relapsed or refractory DLBCL, glofitamab provides an alternative treatment option for patients having failed other systemic therapies or for whom targeted therapies -

  10. Drug

    Naphazoline

    go.drugbank.com/drugs/DB06711
    Approved

    Naphazoline was first developed in 1942 as a nasal formulation for congestion[A176609].

    Mixtures: Visine for Allergy With Antihistamine, Clear Eyes for Dry Eyes Plus Redness ReliefCategories: Adrenergic alpha-1 Receptor Agonists, Adrenergic alpha-2 Receptor Agonists